NETRF announces $3.5 million in research grants to improve neuroendocrine tumor treatment

NETRF announces $3.5 million in research grants to improve neuroendocrine tumor treatment

Largest genome study sheds light on how genetic glitches trigger tumor formation NETRF is supporting a new pioneering approach to NET immunotherapy with a Petersen Accelerator Award to Steven Libutti, MD, Rutgers Cancer Institute of New Jersey, to characterize a novel immune regulator called B7x to determine whether it has a role in shutting off the body's immune response to fight against pancreatic NETs. This round of funding features multiple new fronts for NETRF. To help grow the NET scientific workforce, the Foundation granted two inaugural Mentored Awards for early career researchers, one of which was funded by an educational grant from Ipsen. There were also new areas of NET inquiry. For the first time, NETRF is funding pheochromocytoma and paraganglioma research, including an evaluation of a novel radiotracer for imaging adrenal NETs. NETRF also funded four research projects in lung NETs, an area that has not previously received the attention of other NET sites. These lung studies include: Conducting single-cell genomic analyses to understand how lung NETs form, grow, and spread. Mapping the cellular networks of typical and atypical lung NETs to find biomarkers that help predict a tumor's aggressiveness. Characterizing the molecular makeup of a newly identified, aggressive lung NET called "supra-carcinoid." Determining the sociodemographic and geographic patterns of lung NETs in California. Advances in NET research have been hampered by the lack of effective laboratory disease models, and a limited understanding of the molecular and genetic profiles of NETs. Now that we are making strong headway along these lines, we can finally begin to drill deeper with greater specificity, to identify and explore new strategies for treating NETs." John Kanki, PhD, NETRF director of research Source:



Also in Industry News

How to decide whether or not to start treatment for prostate cancer?
How to decide whether or not to start treatment for prostate cancer?

0 Comments

How to decide whether or not to start treatment for prostate cancer?

Read More

Analysis of the SARS-CoV-2 proteome via visual tools
Analysis of the SARS-CoV-2 proteome via visual tools

0 Comments

Analysis of the SARS-CoV-2 proteome via visual tools

Read More

$65m investment increases British Patient Capital’s exposure to life sciences and health technology
$65m investment increases British Patient Capital’s exposure to life sciences and health technology

0 Comments

$65m investment increases British Patient Capital’s exposure to life sciences and health technology

Read More